Insmed vs Royalty Pharma
Insmed (INSM) and Royalty Pharma (RPRX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $31B
- Last close
- $141.33
- 12 months
- −29.2%
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
At a glance
- The biggest part of Insmed's revenue is ARIKAYCE, 72% of the total in its last annual report.
- By market value, Royalty Pharma ($39.4B) is about 1.3 times Insmed ($31.0B).
- Over the last 12 months Insmed's share price moved −29.2% and Royalty Pharma's +78.3%; against the S&P 500 that is −34.9 points and +72.6 points.
- In their last fiscal years Insmed kept -210.5% of revenue as net income and Royalty Pharma 32.4%.
- In the last 90 days insiders reported 0 open-market purchases at Insmed and 0 at Royalty Pharma; members of Congress disclosed 0 trades in Insmed and 0 in Royalty Pharma.
- Next results: Insmed Feb 17, 2027, Royalty Pharma Feb 9, 2027.
How each one makes money: Insmed revenue · Royalty Pharma revenue
Share prices on one chart
Insmed and Royalty Pharma, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Insmed INSMNASDAQ · Pharmaceutical Preparations | Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $31B | $39.4B |
| Revenue, last fiscal year | $606M | $2.38B |
| Net income, last fiscal year | −$1.28B | $771M |
| Net marginNet income as a share of revenue | -210.5% | 32.4% |
| Free cash flow | −$968M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Insmed different from Royalty Pharma?
Insmed (INSM) is in Pharmaceutical Preparations on NASDAQ, with $606M of revenue in its last fiscal year and a net margin of -210.5%. Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. The biggest part of Insmed's revenue is ARIKAYCE, 72% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Insmed and Royalty Pharma compare in size?
Royalty Pharma has the larger market value: Insmed $31B and Royalty Pharma $39.4B, at the last close.
Whose share price rose more over the last 12 months, INSM or RPRX?
Over the last 12 months Insmed moved −29.2% and Royalty Pharma +78.3%. Past price moves say nothing about the future.
Which has had more insider buying, Insmed or Royalty Pharma?
Since 2006, Insmed insiders reported 81 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade INSM or RPRX?
In the last 12 months, members of Congress disclosed 1 trades in Insmed (INSM) and 0 in Royalty Pharma (RPRX).
When did insiders last buy INSM and RPRX?
Insmed: May 22, 2025. Royalty Pharma: Jun 28, 2023.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Insmed pageRoyalty Pharma pageRare insider trades this weekAll comparisons
https://oqro.io/compare/insm-vs-rprx

